The ‘ PD Warrior ’ exercise programme improves motor outcomes and quality of life in patients with early Parkinson disease: results of a pilot study
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Claire Tucak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Physiotherapy Department, Hollywood Private Hospital, Nedlands, Western Australia, Australia. Hauptthemen laut MEDLINE: Parkinson Disease, Quality of Life, Exercise Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hollywood Private Hospital Research Foundation.
Abstract (Originalsprache)
Background ‘PD Warrior’ (PDW) is a popular exercise programme for Parkinson disease; however, there are no published studies on the outcomes of the programme.
Aims
To investigate short‐term functional and quality of life (QoL) outcomes after the PDW 10‐week programme in a pilot study of individuals with early Parkinson Disease (PD).
Methods
Twenty individuals with PD (Hoehn & Yahr 1–3) attending a hospital outpatient clinic were recruited into the PDW 10‐week programme, comprising a weekly 1‐h supervised class complemented by an individualised daily home exercise programme. Participants had the following assessments at baseline and after completion of the programme: Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS‐UPDRS) Part III, timed up‐and‐go (TUG), 10‐m walk test (10mWT), 6‐min walking test (6MWT), balance tests, fine motor skills, 7‐day Parkinson KinetiGraph (PKG) and PDQ‐39 QoL scale.
Results
Seventeen individuals completed the programme. Significant improvements were observed in MDS‐UPDRS motor score ( P = 0.019, d = 0.68, MCID 7); 6MWT distance ( P < 0.001, d = 1.16); walking time during motor or cognitive dual tasking ( P = 0.006, d = 0.77; P = 0.005, d = 0.79, respectively); and the PDQ‐39 emotional well‐being subdomain ( P = 0.009; MCID 4.2); as well as improvements trending to significance in bradykinesia ( P = 0.025, d = 0.73), 10mWT walking time ( P = 0.023, d = 0.61) and borderline improvement in balance ( P = 0.056, d = 0.50).
Conclusions
The outcomes of this study support the efficacy of the PDW programme in individuals with early PD and provide justification for future trials and investigation of its effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Physiotherapy Department, Hollywood Private Hospital, Nedlands, Western Australia, Australia.
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia.
- Physiotherapy Department, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
- University of Western Australia, Perth, Western Australia, Australia.
- Curtin School of Population Health, Clinical Trials Enabling Platform, Curtin University, Perth, Western Australia, Australia.
- Queen Elizabeth II Medical Centre, Perth, Western Australia, Australia.
ORCID-Profile: Claire Tucak
Förderung
- Hollywood Private Hospital Research Foundation
Zitieren
APA
Tucak, C., Chih, H., Mastaglia, F., & Rodrigues, J. (2024). The ‘ PD Warrior ’ exercise programme improves motor outcomes and quality of life in patients with early Parkinson disease: results of a pilot study. Internal Medicine Journal. https://doi.org/10.1111/imj.16301
Vancouver
Tucak C, Chih H, Mastaglia F, Rodrigues J. The ‘ PD Warrior ’ exercise programme improves motor outcomes and quality of life in patients with early Parkinson disease: results of a pilot study. Internal Medicine Journal. 2024. doi:10.1111/imj.16301
BibTeX
@article{Tucak2024,
author = {Tucak, Claire and Chih, HuiJun and Mastaglia, Frank and Rodrigues, Julian},
title = {The ‘ PD Warrior ’ exercise programme improves motor outcomes and quality of life in patients with early Parkinson disease: results of a pilot study},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16301}
}
EUVIMED